Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Based Review of GLP-1/GIP Agonists for Fitness and Wellness ProfessionalsGilbert, AZ, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting event.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...